The applications for the first generics of apixaban (Eliquis, Bristol-Meyers Squibb) tablets were approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
All News
Advertisement
Ubrogepant is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved by the agency for the acute treatment of migraine.
Advertisement
Advertisement
Baclofen use, particularly at higher doses, may result in an increased risk of encephalopathy among patients with chronic kidney disease.
Officials with the FDA have granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi-Sankyo) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer that have received 2 or more prior anti-HER2-based regimens in the metastatic setting.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Opinion: Pharmacists Are Critical to Ensure Safe, Ethical Integration of AI in Health Care
2
FDA Removes Black Boxed Warning From Hormone Therapies for Menopause
3
Major Review Finds No Link Between Maternal Tylenol and Autism Spectrum Disorder, ADHD
4
Advanced Wearable Accelerometer Shows Promise in Detecting Functional Capacity and Outcomes in Heart Failure Patients
5
